Physician profile
Mark F Hoerman
NPI 1366440984
$761.76
in general payments reported to CMS, 2019-2025
14 companies · $288 in 2025
The $288 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $234 · 2020: $31.71 · 2024: $209 · 2025: $288.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $462 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $462.35 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $188.92 | 2019-2025 | Airsupra, Breztri, Tezspire |
| Glaxosmithkline, LLC. | $133.45 | 2019-2025 | Nucala, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.84 | 2019-2025 | Ofev |
| Grifols USA, LLC | $66.23 | 2025 | Prolastin-C Liquid |
| Insmed, INC. | $62.66 | 2019-2025 | Arikayce |
| Advanced Respiratory, INC | $54.35 | 2019 | |
| Inspire Medical Systems, INC. | $34.01 | 2025 | Inspire |
| Amgen INC. | $34.00 | 2025 | |
| Allergan, INC. | $31.19 | 2019 | |
| Verona Pharma, INC. | $27.92 | 2025 | Ohtuvayre |
| Sunovion Pharmaceuticals INC. | $20.56 | 2019 | |
| Eisai INC. | $16.38 | 2019 | |
| Genentech USA, INC. | $15.50 | 2019 | |
| Biomerieux INC | $7.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Hoerman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.